SMMT 8-K: SEC filing
Summit Therapeutics
Filed with the SEC on · accession 0001599298-26-000094
SMMT filed a 8-K (current report) with the SEC on Nov 18, 2026. Summit Therapeutics announced the planned initiation of the global Phase III HARMONi-10 trial evaluating ivonescimab versus durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III non-small cell lung cancer.
Summary of the filing
Summit Therapeutics announced the planned initiation of the global Phase III HARMONi-10 trial evaluating ivonescimab versus durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III non-small cell lung cancer. Global clinical trial site activations are expected to begin in Q4 2026.
Key details
✦ Ask GOAX AI about this filing — what it means for SMMT, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for SMMT?
Click hereFrequently asked questions
What did SMMT file with the SEC on Nov 18, 2026?
SMMT filed a 8-K (SEC filing). Summit Therapeutics announced the planned initiation of the global Phase III HARMONi-10 trial evaluating ivonescimab versus durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III non-small cell lung cancer. Global clinical trial site activations are expected to begin in Q4 2026.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other SMMT SEC filings
- 8-K · Fda rejectionNov 16, 2026
- 8-K · SEC filingNov 4, 2026
- 8-K · Shelf registrationNov 4, 2026
- 10-Q · SEC filingNov 4, 2026
- DEF 14A · SEC filingOct 19, 2026
- 8-K · Material agreementSep 29, 2026
- 8-K · Fda approvalSep 15, 2026
- 8-K · Fda approvalSep 14, 2026
- 8-K · Fda approvalSep 3, 2026
- 8-K · Fda approvalAug 26, 2026
Get alerts when SMMT files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days